Diagnostic performance of PAX1 methylation as a biomarker for cervical lesions: a clinical study and meta-analysis
PAX1 methylation demonstrates high diagnostic accuracy for cervical cancer and is a promising noninvasive biomarker for screening and triage. Further studies are needed to validate its clinical utility in diverse populations and to explore its potential role in monitoring lesion progression or regression, particularly in women managed with conservative approaches.
Authors
- Jiahui Dai (ORCID: https://orcid.org/0000-0002-6874-7114)
- Ruoxuan Sun (ORCID: https://orcid.org/0000-0001-5981-412X)
- Man Yin
- Yunfei Wang (ORCID: https://orcid.org/0009-0006-6530-3119)
Institutions
- Gynecologic Oncology Group (US)
- Wuhan University (CN)
- HKUST Shenzhen Research Institute (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Peking University Shenzhen Hospital (CN)
- Affiliated Hospital of Jining Medical University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1080/07853890.2025.2583319
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06